Circulating tumor cells will lead liquid biopsy sales through 2036 with a 70.0% share of the biomarker type segment. The market value stood at USD 6.4 billion in 2025 and is forecast to reach USD 29.2 billion by 2036 across key growth regions including China, India, and Germany.